In 2023, there were approximately 750.5 deaths by all causes per 100,000 inhabitants in the United States. This statistic shows the death rate for all causes in the United States between 1950 and 2023. Causes of death in the U.S. Over the past decades, chronic conditions and non-communicable diseases have come to the forefront of health concerns and have contributed to major causes of death all over the globe. In 2022, the leading cause of death in the U.S. was heart disease, followed by cancer. However, the death rates for both heart disease and cancer have decreased in the U.S. over the past two decades. On the other hand, the number of deaths due to Alzheimer’s disease – which is strongly linked to cardiovascular disease- has increased by almost 141 percent between 2000 and 2021. Risk and lifestyle factors Lifestyle factors play a major role in cardiovascular health and the development of various diseases and conditions. Modifiable lifestyle factors that are known to reduce risk of both cancer and cardiovascular disease among people of all ages include smoking cessation, maintaining a healthy diet, and exercising regularly. An estimated two million new cases of cancer in the U.S. are expected in 2025.

In the United States, the leading causes of death among women are heart disease and cancer. Heart disease and cancer are similarly the leading causes of death among U.S. men. In 2022, heart disease accounted for **** percent of all deaths among women in the United States, while cancer accounted for **** percent of deaths. COVID-19 was the third leading cause of death among both men and women in 2020 and 2021, and the fourth leading cause in 2022. Cancer among women in the U.S. The most common types of cancer among U.S. women are breast, lung and bronchus, and colon and rectum. In 2025, there were around ******* new breast cancer cases among women, compared to ******* new cases of lung and bronchus cancer. Although breast cancer is the most common form of cancer among women in the United States, lung and bronchus cancer causes the highest number of cancer deaths. In 2025, around ****** women were expected to die from lung and bronchus cancer, compared to ****** from breast cancer. Breast cancer Although breast cancer is the second most deadly form of cancer among women, rates of death have decreased over the past few decades. This decrease is possibly due to early detection, progress in therapy, and increasing awareness of risk factors. In 2023, the death rate due to breast cancer was **** per 100,000 population, compared to a rate of **** per 100,000 in the year 1990. The state with the highest rate of deaths due to breast cancer is Oklahoma, while South Dakota had the lowest rates.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

This dataset contains counts of deaths for California as a whole based on information entered on death certificates. Final counts are derived from static data and include out-of-state deaths to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all deaths that occurred during the time period. Deaths involving injuries from external or environmental forces, such as accidents, homicide and suicide, often require additional investigation that tends to delay certification of the cause and manner of death. This can result in significant under-reporting of these deaths in provisional data.

The final data tables include both deaths that occurred in California regardless of the place of residence (by occurrence) and deaths to California residents (by residence), whereas the provisional data table only includes deaths that occurred in California regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by age, gender, race-ethnicity, and death place type. Deaths due to all causes (ALL) and selected underlying cause of death categories are provided. See temporal coverage for more information on which combinations are available for which years.

The cause of death categories are based solely on the underlying cause of death as coded by the International Classification of Diseases. The underlying cause of death is defined by the World Health Organization (WHO) as "the disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury." It is a single value assigned to each death based on the details as entered on the death certificate. When more than one cause is listed, the order in which they are listed can affect which cause is coded as the underlying cause. This means that similar events could be coded with different underlying causes of death depending on variations in how they were entered. Consequently, while underlying cause of death provides a convenient comparison between cause of death categories, it may not capture the full impact of each cause of death as it does not always take into account all conditions contributing to the death.

As of 2022, the third leading cause of death among teenagers aged 15 to 19 years in the United States was intentional self-harm or suicide, contributing around 17 percent of deaths among age group. The leading cause of death at that time was unintentional injuries, contributing to around 37.4 percent of deaths, while 21.8 percent of all deaths in this age group were due to assault or homicide. Cancer and heart disease, the overall leading causes of death in the United States, are also among the leading causes of death among U.S. teenagers. Adolescent suicide in the United States In 2021, around 22 percent of students in grades 9 to 12 reported that they had seriously considered attempting suicide in the past year. Female students were around twice as likely to report seriously considering suicide compared to male students. In 2022, Montana had the highest rate of suicides among U.S. teenagers with around 39 deaths per 100,000 teenagers, followed by South Dakota with a rate of 33 per 100,000. The states with the lowest death rates among adolescents are New York and New Jersey. Mental health treatment Suicidal thoughts are a clear symptom of mental health issues. Mental health issues are not rare among children and adolescents, and treatment for such issues has become increasingly accepted and accessible. In 2021, around 15 percent of boys and girls aged 5 to 17 years had received some form of mental health treatment in the past year. At that time, around 35 percent of youths aged 12 to 17 years in the United States who were receiving specialty mental health services were doing so because they had thought about killing themselves or had already tried to kill themselves.

This dataset contains counts of deaths for California counties based on information entered on death certificates. Final counts are derived from static data and include out-of-state deaths to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all deaths that occurred during the time period. Deaths involving injuries from external or environmental forces, such as accidents, homicide and suicide, often require additional investigation that tends to delay certification of the cause and manner of death. This can result in significant under-reporting of these deaths in provisional data.

The final data tables include both deaths that occurred in each California county regardless of the place of residence (by occurrence) and deaths to residents of each California county (by residence), whereas the provisional data table only includes deaths that occurred in each county regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by age, gender, race-ethnicity, and death place type. Deaths due to all causes (ALL) and selected underlying cause of death categories are provided. See temporal coverage for more information on which combinations are available for which years.

The cause of death categories are based solely on the underlying cause of death as coded by the International Classification of Diseases. The underlying cause of death is defined by the World Health Organization (WHO) as "the disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury." It is a single value assigned to each death based on the details as entered on the death certificate. When more than one cause is listed, the order in which they are listed can affect which cause is coded as the underlying cause. This means that similar events could be coded with different underlying causes of death depending on variations in how they were entered. Consequently, while underlying cause of death provides a convenient comparison between cause of death categories, it may not capture the full impact of each cause of death as it does not always take into account all conditions contributing to the death.

According to the data from 2025, some 16 percent of respondents said that rising health care costs were the most important health issue facing the United States. Cancer ranked second on the list with 15 percent. Issues with healthcare costsCurrently, the most urgent problem facing American healthcare is the high costs of care. The high expense of healthcare may deter people from getting the appropriate treatment when they need medical care or cause them to completely forego preventative care visits. Many Americans reported that they may skip prescription doses or refrain from taking medication as prescribed due to financial concerns. Such health-related behavior can result in major health problems, which may raise the long-term cost of care. Inflation, medical debt, and unforeseen medical expenses have all added to the burden that health costs are placing on household income. Gun violence issueThe gun violence epidemic has plagued the United States over the past few years, yet very little has been done to address the issue. In recent years, gun violence has become the leading cause of death among American children and teens. Even though more than half of Americans are in favor of tougher gun control regulations, there is little political will to strongly reform the current gun law. Gun violence has a deep traumatic impact on survivors and society, it is developing into a major public health crisis in the United States.

As of 2023, the countries with the highest death rates worldwide were Monaco, Bulgaria, and Latvia. In these countries, there were ** to ** deaths per 1,000 people. The country with the lowest death rate is Qatar, where there is just *** death per 1,000 people. Leading causes of death The leading causes of death worldwide are, by far, cardiovascular diseases, accounting for ** percent of all deaths in 2021. That year, there were **** million deaths worldwide from ischaemic heart disease and **** million from stroke. Interestingly, a worldwide survey from that year found that people greatly underestimate the proportion of deaths caused by cardiovascular disease, but overestimate the proportion of deaths caused by suicide, interpersonal violence, and substance use disorders. Death in the United States In 2023, there were around **** million deaths in the United States. The leading causes of death in the United States are currently heart disease and cancer, accounting for a combined ** percent of all deaths in 2023. Lung and bronchus cancer is the deadliest form of cancer worldwide, as well as in the United States. In the U.S. this form of cancer is predicted to cause around ****** deaths among men alone in the year 2025. Prostate cancer is the second-deadliest cancer for men in the U.S. while breast cancer is the second deadliest for women. In 2023, the tenth leading cause of death in the United States was COVID-19. Deaths due to COVID-19 resulted in a significant rise in the total number of deaths in the U.S. in 2020 and 2021 compared to 2019, and it was the third leading cause of death in the U.S. during those years.

In 2022, the leading causes of death among children and adolescents in the United States aged 10 to 14 were unintentional injuries, intentional self-harm (suicide), and cancer. That year, unintentional injuries accounted for around 25 percent of all deaths among this age group. Leading causes of death among older teens Like those aged 10 to 14 years, the leading cause of death among older teenagers in the U.S. aged 15 to 19 years is unintentional injuries. In 2022, unintentional injuries accounted for around 37 percent of all deaths among older teens. However, unlike those aged 10 to 14, the second leading cause of death among teens aged 15 to 19 is assault or homicide. Sadly, the third leading cause of death among this age group is suicide, making suicide among the leading three causes of death for both age groups. Teen suicide Suicide remains a major problem among teenagers in the United States, as reflected in the leading causes of death among this age group. It was estimated that in 2021, around 22 percent of high school students in the U.S. considered attempting suicide in the past year, with this rate twice as high for girls than for boys. The states with the highest death rates due to suicide among adolescents aged 15 to 19 years are Montana, South Dakota, and New Mexico. In 2022, the death rate from suicide among this age group in Montana was 39 per 100,000 population. In comparison, New York, the state with the lowest rate, had just five suicide deaths among those aged 15 to 19 years per 100,000 population.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

According to Cognitive Market Research, the Global Heparin Market Size is USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2024 to 2033.

North America held largest share of XX% in the year 2024 
Europe held share of XX% in the year 2024 
Asia-Pacific held significant share of XX% in the year 2024 
South America held significant share of XX% in the year 2024
Middle East and Africa held significant share of XX% in the year 2024 

Market Dynamics of Heparin Market

Key Drivers for Heparin Market

Increasing Prevalence of Cardiovascular Diseases is inflating the heparin market.

Chronic blood diseases cases are increasing exponentially and are expected to propel the global antiplatelet drugs market. Chronic disease prevalence increase is due to drive the market. The increase in the incidence of cardiovascular diseases is one of the key drivers of the growth rate of the antiplatelet drugs market. Cardiovascular disease is the leading cause of mortality in both developed and developing economies.

It is estimated by the Centers for Disease Control and Prevention (CDC) that more than 8,00,000 people in the United States pass away every year due to stroke and other cardiovascular diseases. For instance, a World Health Organization (WHO) study has reported that cardiovascular diseases (CVDs) are responsible for approximately 31% of total patient deaths every year. For instance, in 2022, as noted in a National Library of Medicine study, cardiovascular diseases (CVD) were responsible for approximately 19.8 million deaths globally, necessitating the effective treatment of heparin in controlling thrombosis and mitigating mortality rates of CVD-related complications. The increasing rate of CVDs is a major factor behind the need for heparin: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of cardiovascular mortality worldwide. VTE risk doubles every decade after the age of 40, and is also very high among inpatients, with the incidence of 10 to 20 cases per 1,000 admissions. Atrial fibrillation, a prevalent cardiac arrhythmia, occurs in an estimated 12.1 million Americans by 2030, and this boosts the demand for anticoagulant drugs such as heparin. These highlights the imperative function of heparin in treating and preventing cardiovascular disease-related complications, thus fueling market expansion.

Rising number of geriatric populations increases CVD which in turn increases the usage of heparin and the market is expanding.

Growing geriatric population globally is expected to support heparin drugs demand since this group is susceptible to heart diseases. The population of individuals over 65 years is expected to double in the future years. The old-aged individuals are susceptible to many chronic diseases like cardiovascular diseases, which can encourage the demand for heparin drugs globally. There were approximately 382 million aged people, aged 60 years and older, in the world in 2017 and it is projected to grow to 2.1 billion by 2050, as per the United Nations. Older adults with cardiovascular disease (CVD) often face the challenge of managing multiple chronic or multimorbid conditions, leading to a significant drug burden that complicates their treatment. With the prevalence of multimorbidity ranging from 30% to 83% in individuals aged 65 and older, cardiovascular comorbidities are frequently reported as the most common combination of chronic diseases. This situation is further exacerbated by issues such as functional decline and complex geriatric syndromes (GSs), which are major concerns in the management of this population. Notably, polypharmacy, defined as the simultaneous use of five or more medications, affects 26.3% to 40% of older adults, with excessive polypharmacy impacting around 10%. The incidence of polypharmacy can reach alarming rates, with studies indicating a 53% to 87% incidence over three years. The presence of geriatric syndromes, which can affect 10% to 60% of older adults, significantly contributes to declines in functional status and quality of life, increased hospital admissions, and higher mortality rates. Additionally, frailty, characterized by a reduced physiological reserve and increased vulnerability to stressors, affects 10% of older adults, with rates as high as 60% in those with severe ...

Find data on deaths of Massachusetts residents. Information is obtained from death certificates received by the Registry of Vital Records and Statistics.

According to Cognitive Market Research, the global Liver Cirrhosis Market size will be XX million by 2033, whereas its compound annual growth rate (CAGR) will be XX% from 2025 to 2033. • North America held the largest share of the global Liver Cirrhosis market around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Europe accounted for a share of over XX% of the global market size of USD XX million. • Asia Pacific held a market share of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • The Latin American market is around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033.

Market Dynamics of the Liver Cirrhosis Market

Key Drivers of the Liver Cirrhosis Market

Increased incidence of liver disease significantly boosts the market: Globally, liver disease is still exceedingly prevalent. A sedentary lifestyle, lack of exercise, and particularly poor food are the main causes of liver disease in many people. As the population ages, autoimmune disorders including hepatitis and non-alcoholic fatty liver are becoming more common. The notable rise in instances can also be attributed to alcohol intake above. The global market for liver disease treatment will be driven by the rising availability of medicines.

The increasing geriatric population will expand the liver cirrhosis drugs market: Globally, the aging population is a challenge, and countries are dealing with several issues, such as providing long-term care for those who have a high prevalence of chronic illnesses, such as liver disorders. Maintaining hepatic function, daily living activities, and the quality of life for individuals with liver disease all depend on the management of cirrhosis and hepatitis. The aging-related characteristics must be taken into account while choosing treatment methods and the appropriate dose of currently available medications, even though a wide range of therapeutic choices, including freshly created drugs and procedures, are accessible.

Targeted therapies and personalized medicine drive the growth of liver cirrhosis market: Targeted therapies and personalized medicine offer a more precise approach to treating liver cirrhosis, moving beyond one-size-fits-all treatments to consider individual patient profiles and disease characteristics. This approach involves identifying specific molecular pathways, genetic variations, and biomarkers that contribute to cirrhosis and its complications, allowing for the development of drugs and therapies that target these specific mechanisms. Sequencing technologies have made it possible to identify genetic and epigenetic changes in patients with cirrhosis that can be used to inform treatment.

Key Restraints for Liver Cirrhosis Market

The high cost of drugs may hamper the market growth: The high expense of the medications, treatments, and operations needed to treat liver disease greatly impedes market growth. Comorbidities, cirrhosis, and its consequences increase the burden of chronic illness. Market participants can enhance the safety and effectiveness of these medications by using the newest innovations and technology. However, both this technology and the process of creating new medications come at a great expense. Costs are further increased by expensive regulatory licenses and multiple drug testing. Therefore, the market expansion would be driven by the high expense of treating liver illnesses.

Insufficient Early Diagnosis and Awareness: Liver cirrhosis frequently goes undetected until it reaches advanced stages, primarily because of its asymptomatic early development. A lack of public awareness regarding risk factors such as alcohol abuse and viral hepatitis hinders timely medical intervention. Additionally, inadequate screening programs in specific areas worsen the situation, restricting early treatment options and negatively impacting patie...

In 2022, the most significant cause of death among men in the United States was heart disease, which contributed to **** percent of deaths. COVID-19 was the third leading cause of death among U.S. men in both 2020 and 2021, and the fourth leading cause in 2022. This statistic shows the distribution of the ** leading causes of death among men in the United States from 2020 to 2022.

According to Cognitive Market Research , the global Targeted Cancer Drugs Market size will be XX million by 2033, whereas its compound annual growth rate (CAGR) will be XX% from 2025 to 2033. • North America held the largest share of the global Targeted Cancer Drugs market around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Asia Pacific held a market share of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Europe accounted for a share of over XX% of the global market size of USD XX million. • The Latin American market is around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. Market Dynamics of the Targeted Cancer Drugs Market

Key Drivers of the Targeted Cancer Drugs Market

Rising incidence of cancer enhances the targeted cancer drugs market growth

Tobacco use, high body mass index, alcohol usage, low intake of fruits and vegetables, and lack of physical activity are responsible for about one-third of cancer-related risk. Furthermore, one significant risk factor for lung cancer is air pollution. About 30% of cancer cases in low- and lower-middle-income nations are caused by diseases that cause cancer, such as hepatitis and the human papillomavirus (HPV). How frequently a cancer arises (incidence) and how long people typically live after being diagnosed (survival) are the two factors that determine cancer prevalence. This indicates that the most prevalent malignancies with the longest survival have the highest prevalence counts. Compared to a less common cancer with a longer survival, a common cancer with a shorter survival may have a lower prevalence count. For instance, according to the American Cancer Society 2023, non-Hodgkin lymphoma, a less common cancer, has a higher prevalence rate than lung cancer, despite lung cancer being one of the most common malignancies in the US. There are more persons living after a diagnosis of non-Hodgkin lymphoma than after a diagnostic of lung cancer because those with non-Hodgkin lymphoma have a higher chance of surviving longer than those with lung cancer. There were 1,777,566 new cases of cancer reported in the US in 2021. An estimated 608,366 Americans lost their lives to cancer in 2022. https://www.cdc.gov/cancer/data/index.html In the twenty-first century, cancer is a significant social, public health, and economic issue, accounting for about one in six fatalities (16.8%) and one in four deaths (22.8%) from noncommunicable diseases (NCDs) globally. Three out of ten premature deaths worldwide are caused by NCDs (30.3% in people aged 30 to 69), and in 177 out of 183 nations, it ranks among the top three causes of death for this age group. Apart from being a significant hindrance to extending life expectancy, cancer is linked to significant societal and macroeconomic expenses, which differ in extent depending on the type of cancer, location, and gender. For instance, according to International Agency for Research on Cancer in 2022, there were about 20 million new cases of cancer, including nonmelanoma skin cancers (NMSCs), and 9.7 million cancer-related deaths. According to estimates, one in five men and women will get cancer at some point in their lives, while one in nine men and one in twelve women will pass away from the disease. With about 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers), lung cancer was the most commonly diagnosed cancer in 2022. It was followed by stomach (4.9%), colorectum (9.6%), prostate (7.3%), and female breast (11.6%) cancers. With an anticipated 1.8 million deaths (18.7%), lung cancer was also the most common cause of cancer-related mortality. Colorectal (9.3%), liver (7.8%), female breast (6.9%), and stomach (6.8%) cancers were next in line. The two most common cancers in both men and women were lung and breast cancer. https://acsjournals.onlinelibrary.wile...

The Youth Risk Behavior Surveillance System (YRBSS) is a set of surveys that monitor priority health risk behaviors and experiences that contribute markedly to the leading causes of death, disability, and social problems among youth of grade 9 -12 in the United States. The surveys are administered every other year and it is maintained by the Centers for Disease Control and Prevention (CDC). A total of 107 questionnaire are asked. Some of the health-related behaviors and experiences monitored are: * Student demographics: sex, sexual identity, race and ethnicity, and grade * Youth health behaviors and conditions: sexual, injury and violence, bullying, diet and physical activity, obesity, and mental health, suicide attempt * Substance use behaviors: electronic vapor product and tobacco product use, alcohol use, and other drug use * Student experiences: parental monitoring, school connectedness, unstable housing, and exposure to community violence The dataset is used by a group of graduate students from Texas State University for 2025 TXST Open Datathon. The main YRBSS dataset includes data of multiple years, various states, district. For analyzing demographic variations associated with suicide, the 1991–2023 combined district dataset (https://www.cdc.gov/yrbs/files/sadc_2023/HS/sadc_2023_district.dat) is used, which offers a broad historical perspective on trends across different groups. To examine the preventive measures and develop a predictive model for suicide risk, the 2023 dataset (https://www.cdc.gov/yrbs/files/2023/XXH2023_YRBS_Data.zip) was used, ensuring the inclusion of the most recent behavioral and attributes. Please review the 2023 YRBS Data User's Guide by CDC for further information.

Number and percentage of deaths, by month and place of residence, 1991 to most recent year.

Chronic Disease Management Market Outlook

The global chronic disease management market size was valued at USD 4.5 billion in 2023 and is projected to reach USD 9.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.1% during the forecast period. The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, coupled with the rising adoption of healthcare IT solutions, is driving the growth of this market. Chronic diseases are leading causes of mortality and morbidity worldwide, prompting healthcare providers and governments to invest heavily in management solutions to improve patient outcomes and reduce healthcare costs.

One of the primary growth factors propelling the chronic disease management market is the escalating burden of chronic diseases globally. With aging populations and lifestyle changes, conditions such as cardiovascular diseases, diabetes, and chronic respiratory diseases are becoming more prevalent. This surge in chronic diseases necessitates robust management solutions that can effectively monitor and manage patient health, thereby reducing hospital readmissions and improving quality of life. Innovations in telemedicine and remote monitoring technologies are also contributing to the market's expansion, enabling continuous patient care and timely interventions.

Technological advancements in healthcare IT is another significant driver of the chronic disease management market. The integration of artificial intelligence (AI) and machine learning algorithms in chronic disease management solutions is enhancing predictive analytics, enabling early diagnosis and personalized treatment plans. These technologies facilitate the collection and analysis of large volumes of patient data, providing healthcare providers with actionable insights to optimize care delivery. Furthermore, the adoption of electronic health records (EHR) and mobile health applications is streamlining patient management, improving communication between patients and healthcare professionals, and promoting patient engagement in their own health management.

Government initiatives and policies aimed at improving public health are also fueling the growth of the chronic disease management market. Many governments across the globe are implementing programs to promote preventive care and chronic disease management to reduce the financial burden on healthcare systems. These initiatives include funding for healthcare IT infrastructure, patient education programs, and reimbursement policies for chronic disease management services. Additionally, private sector investments in healthcare innovation and collaborations between technology companies and healthcare providers are further accelerating market growth.

Disease Registry Software plays a pivotal role in the chronic disease management landscape by providing a comprehensive platform for tracking and analyzing patient data. This software enables healthcare providers to maintain detailed records of patients with chronic conditions, facilitating better monitoring and management of their health. By integrating with electronic health records and other healthcare IT systems, Disease Registry Software offers a centralized repository of patient information, allowing for seamless access and sharing of data across different healthcare settings. This enhances the ability of healthcare professionals to deliver personalized care, track disease progression, and implement timely interventions. Moreover, the use of Disease Registry Software supports population health management initiatives by enabling the identification of trends and patterns in chronic disease prevalence, thereby informing public health strategies and resource allocation.

From a regional perspective, North America dominates the chronic disease management market due to its advanced healthcare infrastructure, high adoption of innovative technologies, and proactive government policies. Europe follows closely, driven by its strong focus on improving healthcare outcomes and reducing chronic disease incidence. The Asia Pacific region is witnessing rapid market growth, attributed to increasing healthcare investments, rising prevalence of chronic diseases, and growing awareness about disease management solutions. Latin America and the Middle East & Africa also present significant growth opportunities, driven by improving healthcare infrastructure and increasing government initiatives to combat ch

Overview

New York, NY – June 12, 2025 – Global Spirometers Market size is expected to be worth around US$ 3.4 billion by 2034 from US$ 1.3 billion in 2024, growing at a CAGR of 10.2% during the forecast period 2025 to 2034. In 2023, North America led the market, achieving over 41.7% share with a revenue of US$ 0.5 Billion.

The global spirometer market is experiencing steady expansion, driven by the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. According to the World Health Organization (WHO), over 262 million people were affected by asthma in 2019, and COPD was the third leading cause of death globally, accounting for approximately 3.23 million deaths. This has accelerated the demand for spirometers as essential diagnostic tools in hospitals, clinics, and homecare settings.

Spirometers are non-invasive devices used to measure lung function, particularly the volume and flow of air during inhalation and exhalation. The growing awareness about early diagnosis, rising air pollution levels, and increasing smoking habits have contributed to market expansion. Furthermore, the COVID-19 pandemic highlighted the importance of pulmonary health, spurring demand for both handheld and tabletop spirometry devices.

Technological advancements, such as the integration of wireless connectivity, portable designs, and digital data management, have improved patient monitoring and compliance. These innovations are enhancing diagnostic accuracy and enabling remote respiratory assessments, especially in primary care settings and rural areas.

North America holds the largest market share due to high disease burden, robust healthcare infrastructure, and active government initiatives promoting lung health. Meanwhile, the Asia-Pacific region is projected to witness the fastest growth, driven by urbanization, industrialization, and improving healthcare access.